Skip to content
Sign in
Business opportunities for Pleryon Therapeutics

Compatibility /100

50/100

High potential

Why talk

  1. Complementary sectors: Biotech & life sciences × Deep tech & materials — room for a joint offer or co-selling.
  2. Pleryon Therapeutics is one step ahead of NEOCRETE (Seed): Pleryon Therapeutics can share its playbook.
  3. NEOCRETE likely needs funding for the next round — Pleryon Therapeutics can offer investor introductions (inferred from public profile).

Score anatomy

Each segment is what one dimension adds, out of 100.

Needs ↔ offers5.0Market bridge2.5Customer potential2.8Sector synergy25.0Stage complementarity15.0

Dimension by dimension

Needs ↔ offers

5.0 / 10 pts

Pleryon Therapeutics can help NEOCRETE.

  • NEOCRETE likely needs funding for the next round — Pleryon Therapeutics can offer investor introductions (inferred from public profile).

Market bridge

2.5 / 10 pts

Distant markets.

  • NEOCRETE is based in New Zealand (Oceania): a landing pad on another continent, both ways.

Customer potential

2.8 / 5 pts

Some customer potential.

  • NEOCRETE already has first customers in a related sector (Deep tech & materials): Activator used at commercial scale by Readymix Brunei (case study).

Sector synergy

25.0 / 50 pts

Complementary sectors.

  • Complementary sectors: Biotech & life sciences × Deep tech & materials — room for a joint offer or co-selling.

Stage complementarity

15.0 / 25 pts

Useful peer or mentor link.

  • Pleryon Therapeutics is one step ahead of NEOCRETE (Seed): Pleryon Therapeutics can share its playbook.

How the score works

Each dimension gives a value between 0 and 1, multiplied by its weight; the compatibility is the sum (0–100). Weights for “Peers”: Needs ↔ offers 10, Market bridge 10, Customer potential 5, Sector synergy 50, Stage complementarity 25. Declared needs and offers count fully; when a startup has declared nothing, a few needs/offers are inferred from its public profile (for example, no known traction ⇒ needs customers) and count at half value.

Potential blends compatibility (65%) with the mean global score of both startups (35%): 52/100 — high from 50, medium from 36.